share_log

JMP Securities Maintains Market Outperform on Cellectis, Lowers Price Target to $6

Benzinga Real-time News ·  Jan 19, 2023 07:22

JMP Securities analyst Silvan Tuerkcan maintains Cellectis (NASDAQ:CLLS) with a Market Outperform and lowers the price target from $11 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment